Cancer
Malignant Ovarian Neoplasm
CI-CAN-00003205Explore in graph →
Top-level684 active trials5 approved drugs83 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00003205Explore in graph →
Clinical trials
3,086 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (437)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06433219 | Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302) | completed | Phase 2 | 63 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 13 | Sep 14, 2026 | clinicaltrials |
| NCT05864144 | A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 98 | Sensei Biotherapeutics, Inc.INDUSTRY | 1 | Sep 2, 2026 |
| clinicaltrials |
| NCT05348356 | Nirogacestat in Ovarian Granulosa Cell Tumors | completed | Phase 2 | 53 | SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, GermanyINDUSTRY | 3 | Aug 25, 2026 | clinicaltrials |
| NCT05979298 | Efficacy of Plasmid Elenagen in Combination With Gemcitabine in Patients With Platinum-resistant Ovarian Cancer | completed | Phase 2 | 40 | CureLab OncologyINDUSTRY | 1 | Aug 24, 2026 | clinicaltrials |
| NCT03188432 | Hyperthermic Intraperitoneal Chemotherapy Trial Comparing Quality of Life in Patients With Stage IIIC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 50 | Wake Forest University Health SciencesOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT04902872 | Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 69 | Cybrexa TherapeuticsINDUSTRY | 1 | Aug 20, 2026 | clinicaltrials |
| NCT04415944 | Trial Evaluating Feasibility and Quality of Life of Second Look Laparoscopy With Hyperthermic Intraperitoneal Chemotherapy(HIPEC) | completed | Phase 2 | 10 | Wake Forest University Health SciencesOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT03026062 | Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 2 | 100 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT02101788 | Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer | completed | Phase 2 / Phase 3 | 260 | National Cancer Institute (NCI)NIH | 2 | Aug 4, 2026 | clinicaltrials |
| NCT03180294 | Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer | completed | Phase 2 | 230 | NRG OncologyOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT04387227 | Pembrolizumab and Carboplatin for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 22 | University of WashingtonOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT05185947 | Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis | completed | Phase 2 | 21 | National Cancer Institute (NCI)NIH | 1 | Jun 25, 2026 | clinicaltrials |
| NCT05708950 | A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101) | completed | Phase 1 / Phase 2 | 40 | Kineta Inc.INDUSTRY | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07648745 | Does Cediranib Prevent Bowel Perforation in Platinum-resistant Ovarian Cancer(CEBOC) | completed | Phase 2 | 30 | Prof Gordon JaysonOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT02759588 | Olvi-Vec Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer | completed | Phase 1 / Phase 2 | 46 | Genelux CorporationINDUSTRY | 1 | Jun 12, 2026 | clinicaltrials |
| NCT05964361 | First-in-human Interleukin-15-transpresenting Wilms' Tumor Protein 1-targeting Autologous Dendritic Cell Vaccination in Cancer Patients(IL15-TransDC) | completed | Phase 1 / Phase 2 | 10 | University Hospital, AntwerpOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT03430700 | Trial of Pembrolizumab Following Weekly Paclitaxel for Platinum-resistant Ovarian, Fallopian Tube or Peritoneal Cancer(PROMPT) | completed | Phase 2 | 20 | University College, LondonOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT00959647 | A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study | completed | Phase 2 | 19 | Genentech, Inc.INDUSTRY | 1 | May 8, 2026 | clinicaltrials |
| NCT03797326 | Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) | completed | Phase 2 | 611 | Merck Sharp & Dohme LLCINDUSTRY | 17 | May 4, 2026 | clinicaltrials |
| NCT02122185 | Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 111 | University of ChicagoOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT05198804 | A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer | completed | Phase 1 / Phase 2 | 117 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, IncINDUSTRY | 2 | Mar 18, 2026 | clinicaltrials |
| NCT02867956 | Apatinib and Etoposide in Patients With Platinum Resistant or Refractory Ovarian Cancer | completed | Phase 2 | 35 | Sun Yat-sen UniversityOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT05494580 | Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer | completed | Phase 1 / Phase 2 | 29 | Sun Yat-sen UniversityOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT04332653 | NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 215 | NeoImmuneTechINDUSTRY | 1 | Mar 9, 2026 | clinicaltrials |
| NCT04089189 | Study of IMP4297 in Patients With BRCA1/2 Mutation Ovarian Cancer(SABRINA) | completed | Phase 2 | 93 | Impact Therapeutics, Inc.INDUSTRY | 1 | Jan 28, 2026 | clinicaltrials |
| NCT05041257 | Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers(PICCOLO) | completed | Phase 2 | 79 | AbbVieINDUSTRY | 7 | Jan 9, 2026 | clinicaltrials |
| NCT06173037 | RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer | completed | Phase 2 | 43 | RemeGen Co., Ltd.INDUSTRY | 1 | Jan 7, 2026 | clinicaltrials |
| NCT02001272 | EWOC-1 Trial: Carboplatin +/- Paclitaxel in Vulnerable Elderly Patients With Stage III-IV Advanced Ovarian Cancer(EWOC-1) | completed | Phase 2 | 120 | Hospices Civils de LyonOTHER | 6 | Dec 19, 2025 | clinicaltrials |
| NCT03959761 | Tolerance of Intraperitoneal (IP) Nivolumab After Extensive Debulking Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Ovarian Carcinoma(ICONIC) | completed | Phase 1 / Phase 2 | 22 | Hospices Civils de LyonOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT05001347 | A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors | completed | Phase 2 | 25 | I-Mab Biopharma US LimitedINDUSTRY | 1 | Dec 16, 2025 | clinicaltrials |
| NCT04339140 | Zafirlukast in Treatment of Marker Relapsed Ovarian Cancer | completed | Phase 2 | 5 | Beth Israel Deaconess Medical CenterOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT03249142 | Immunotherapy With Neo-adjuvant Chemotherapy for OVarian Cancer(INeOV) | completed | Phase 1 / Phase 2 | 69 | ARCAGY/ GINECO GROUPOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT03776812 | Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 178 | Corcept TherapeuticsINDUSTRY | 5 | Oct 7, 2025 | clinicaltrials |
| NCT05446870 | Pembrolizumab With Chemotherapy and MK-4830 for Treating Participants With Ovarian Cancer (MK-4830-002) | completed | Phase 2 | 160 | Merck Sharp & Dohme LLCINDUSTRY | 11 | Oct 1, 2025 | clinicaltrials |
| NCT03275506 | PEMBRO With Chemo in Neo Adj Treatment of Ovarian Cancer .(NEOPEMBROV) | completed | Phase 2 | 91 | ARCAGY/ GINECO GROUPOTHER | 1 | Sep 11, 2025 | clinicaltrials |
| NCT04374630 | Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian(PROFECTA-II) | completed | Phase 2 | 150 | Laekna LimitedINDUSTRY | 2 | Sep 10, 2025 | clinicaltrials |
| NCT02498600 | Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 2 | 100 | National Cancer Institute (NCI)NIH | 1 | Aug 29, 2025 | clinicaltrials |
| NCT05815862 | Clinical Study of AL2846 Capsules in the Treatment of Advanced Lung Tumor and Advanced Ovarian Cancer | completed | Phase 2 | 29 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Aug 29, 2025 | clinicaltrials |
| NCT01767675 | Outcomes After Secondary Cytoreductive Surgery With or Without Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Followed by Systemic Combination Chemotherapy for Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 99 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 27, 2025 | clinicaltrials |
| NCT05259696 | Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)(GLIMMER-01) | completed | Phase 1 / Phase 2 | 69 | Palleon Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 20, 2025 | clinicaltrials |
| NCT02327078 | A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204) | completed | Phase 1 / Phase 2 | 307 | Incyte CorporationINDUSTRY | 2 | Aug 14, 2025 | clinicaltrials |
| NCT03314935 | A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors | completed | Phase 1 / Phase 2 | 149 | Incyte CorporationINDUSTRY | 3 | Aug 12, 2025 | clinicaltrials |
| NCT03395080 | A Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer or Carcinosarcoma(P204) | completed | Phase 2 | 111 | Leap Therapeutics, Inc.INDUSTRY | 1 | Aug 1, 2025 | clinicaltrials |
| NCT03267589 | Trial in Patients With Relapsed Ovarian Cancer | completed | Phase 2 | 25 | Nordic Society of Gynaecological Oncology - Clinical Trials UnitOTHER | 3 | Jul 29, 2025 | clinicaltrials |
| NCT03783949 | European Trial on Enhanced DNA Repair Inhibition in Ovarian Cancer(EUDARIO) | completed | Phase 2 | 122 | Universitaire Ziekenhuizen KU LeuvenOTHER | 5 | Jun 11, 2025 | clinicaltrials |
| NCT01309230 | A Trial of FANG™ Vaccine for Participants With Ovarian Cancer | completed | Phase 2 | 39 | Gradalis, Inc.INDUSTRY | 1 | Jun 8, 2025 | clinicaltrials |
| NCT05044871 | Biomarker-driven Targeted Therapy in Patients With Recurrent Platinum-resistant Epithelial Ovarian Cancer(BRIGHT) | completed | Phase 2 | 108 | Tongji HospitalOTHER | 1 | Jun 8, 2025 | clinicaltrials |
| NCT06087289 | A Study to Evaluate the Safety of KAND567, in Combination With Carboplatin Therapy, in Women With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer(KANDOVA) | completed | Phase 1 / Phase 2 | 18 | Novakand Pharma ABINDUSTRY | 3 | Jun 8, 2025 | clinicaltrials |
| NCT04068896 | Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy | completed | Phase 1 / Phase 2 | 89 | NGM Biopharmaceuticals, IncINDUSTRY | 1 | May 29, 2025 | clinicaltrials |
| NCT02713386 | Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 1 / Phase 2 | 147 | NRG OncologyOTHER | 1 | May 25, 2025 | clinicaltrials |
Data updated 15 days agoSource updated Sep 14, 2026source: clinicaltrials